• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    1/1/24 4:30:54 PM ET
    $ADTX
    $BPTS
    $CORT
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • NGM Biopharmaceuticals (NASDAQ:NGM) shares moved upwards by 43.2% to $1.23 during Monday's after-market session. The company's market cap stands at $101.7 million.
    • Cue Health (NASDAQ:HLTH) shares rose 35.38% to $0.22. The market value of their outstanding shares is at $34.0 million.
    • Homology Medicines (NASDAQ:FIXX) stock increased by 12.46% to $0.64. The market value of their outstanding shares is at $36.8 million.
    • Cue Biopharma (NASDAQ:CUE) shares moved upwards by 10.05% to $2.9. The company's market cap stands at $130.8 million.
    • Cadrenal Therapeutics (NASDAQ:CVKD) shares increased by 9.68% to $0.78. The company's market cap stands at $10.1 million.
    • Biophytis (NASDAQ:BPTS) shares moved upwards by 9.05% to $0.73. The company's market cap stands at $7.1 million.

    Losers

    • Corcept Therapeutics (NASDAQ:CORT) shares decreased by 38.4% to $20.0 during Monday's after-market session. The market value of their outstanding shares is at $2.0 billion.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock declined by 31.49% to $2.72. The company's market cap stands at $1.5 million.
    • LumiraDx (NASDAQ:LMDX) shares declined by 23.45% to $0.05. The company's market cap stands at $15.7 million.
    • Aditxt (NASDAQ:ADTX) stock fell 23.45% to $5.06. The market value of their outstanding shares is at $2.2 million.
    • Fresh2 Group (NASDAQ:FRES) stock decreased by 15.74% to $0.75. The market value of their outstanding shares is at $17.7 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) stock declined by 12.69% to $0.64. The market value of their outstanding shares is at $22.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $BPTS
    $CORT
    $CUE

    CompanyDatePrice TargetRatingAnalyst
    Corcept Therapeutics Incorporated
    $CORT
    12/31/2025$30.00Peer Perform → Underperform
    Wolfe Research
    Corcept Therapeutics Incorporated
    $CORT
    12/16/2025Neutral
    UBS
    Corcept Therapeutics Incorporated
    $CORT
    11/18/2025Peer Perform
    Wolfe Research
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    Cue Biopharma Inc.
    $CUE
    3/13/2024$6.00Buy
    Jefferies
    NGM Biopharmaceuticals Inc.
    $NGM
    3/12/2024Outperform → Mkt Perform
    Raymond James
    NGM Biopharmaceuticals Inc.
    $NGM
    2/28/2024Outperform → Market Perform
    TD Cowen
    NGM Biopharmaceuticals Inc.
    $NGM
    2/27/2024Buy → Neutral
    Citigroup
    More analyst ratings

    $ADTX
    $BPTS
    $CORT
    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wilson James N gifted 28,000 shares (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    3/17/26 8:03:54 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mahoney David L exercised 30,000 shares at a strike of $5.86, covered exercise/tax liability with 5,469 shares, gifted 24,531 shares and acquired 24,531 shares (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    3/17/26 7:52:27 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Guyer William exercised 8,233 shares at a strike of $21.65 and sold $296,346 worth of shares (8,233 units at $35.99) (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    3/6/26 4:30:18 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BPTS
    $CORT
    $CUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ADTX
    $BPTS
    $CORT
    $CUE
    SEC Filings

    View All

    SEC Form S-3 filed by Cue Biopharma Inc.

    S-3 - Cue Biopharma, Inc. (0001645460) (Filer)

    3/17/26 11:31:53 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Cue Biopharma Inc.

    DEF 14A - Cue Biopharma, Inc. (0001645460) (Filer)

    3/16/26 4:01:28 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cue Biopharma, Inc. (0001645460) (Filer)

    3/16/26 4:00:40 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BPTS
    $CORT
    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company's lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda Warren as Chief Financial and Business OfficerRaised net proceeds of $10.2M through an underwritten public offeringAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront payments totaling $15M BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to s

    3/16/26 4:05:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADTX
    $BPTS
    $CORT
    $CUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sarraf Pasha bought $99,747 worth of shares (323,857 units at $0.31) (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    1/2/26 4:00:03 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Passeri Daniel R bought $30,900 worth of shares (30,000 units at $1.03), increasing direct ownership by 22% to 164,578 units (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    12/18/24 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    10/17/24 1:58:54 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BPTS
    $CORT
    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Corcept Therapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $30.00

    12/31/25 9:53:16 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Corcept Therapeutics

    UBS initiated coverage of Corcept Therapeutics with a rating of Neutral

    12/16/25 8:47:55 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Corcept Therapeutics

    Wolfe Research initiated coverage of Corcept Therapeutics with a rating of Peer Perform

    11/18/25 8:21:50 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BPTS
    $CORT
    $CUE
    Leadership Updates

    Live Leadership Updates

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma's chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026. "The combination of Lucinda's financial and business acumen together with her extensive background makes the CFBO a key strategic partner in helping drive business growth and Company success, part

    2/12/26 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BPTS
    $CORT
    $CUE
    Financials

    Live finance-specific insights

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

    2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

    2/24/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.

    2/17/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BPTS
    $CORT
    $CUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

    SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

    11/14/24 4:00:17 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

    SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

    10/25/24 12:19:29 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

    SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

    10/4/24 4:15:02 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care